Brokerages Set Disc Medicine, Inc. (NASDAQ:IRON) Price Target at $104.44

Disc Medicine, Inc. (NASDAQ:IRON) has earned an average rating of “Moderate Buy” from the eleven research firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and nine have issued a buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is $104.4444.

A number of research firms have recently commented on IRON. Wall Street Zen raised Disc Medicine from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Wedbush restated an “outperform” rating and set a $88.00 price objective on shares of Disc Medicine in a report on Wednesday, June 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research report on Monday, April 20th. Finally, Morgan Stanley increased their target price on Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a research note on Monday, June 15th.

Disc Medicine Trading Down 1.3%

Shares of IRON opened at $75.01 on Wednesday. The company’s fifty day simple moving average is $70.77 and its 200-day simple moving average is $69.96. The company has a market cap of $2.86 billion, a P/E ratio of -11.33 and a beta of 0.97. The company has a current ratio of 24.00, a quick ratio of 24.00 and a debt-to-equity ratio of 0.04. Disc Medicine has a twelve month low of $40.00 and a twelve month high of $99.50.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($1.65) EPS for the quarter, missing the consensus estimate of ($1.62) by ($0.03). As a group, analysts expect that Disc Medicine will post -6.74 EPS for the current year.

Insider Transactions at Disc Medicine

In other Disc Medicine news, COO Jonathan Yen-Wen Yu sold 18,612 shares of the business’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $69.19, for a total value of $1,287,764.28. Following the completion of the sale, the chief operating officer directly owned 54,324 shares of the company’s stock, valued at $3,758,677.56. The trade was a 25.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Rahul Khara sold 7,500 shares of the company’s stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $70.22, for a total transaction of $526,650.00. Following the completion of the transaction, the insider owned 52,173 shares in the company, valued at $3,663,588.06. This represents a 12.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 105,712 shares of company stock worth $7,597,536. Insiders own 3.76% of the company’s stock.

Institutional Trading of Disc Medicine

Several institutional investors and hedge funds have recently modified their holdings of the stock. Arizona State Retirement System lifted its stake in Disc Medicine by 2.2% in the fourth quarter. Arizona State Retirement System now owns 6,798 shares of the company’s stock worth $540,000 after acquiring an additional 144 shares during the period. Police & Firemen s Retirement System of New Jersey raised its holdings in shares of Disc Medicine by 3.3% in the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 6,716 shares of the company’s stock valued at $533,000 after purchasing an additional 215 shares in the last quarter. AlphaCentric Advisors LLC lifted its position in shares of Disc Medicine by 5.8% in the 1st quarter. AlphaCentric Advisors LLC now owns 3,972 shares of the company’s stock worth $254,000 after purchasing an additional 216 shares during the period. Avanza Fonder AB increased its holdings in Disc Medicine by 14.1% during the fourth quarter. Avanza Fonder AB now owns 1,903 shares of the company’s stock valued at $151,000 after buying an additional 235 shares during the period. Finally, Kennedy Capital Management LLC raised its stake in Disc Medicine by 3.3% in the fourth quarter. Kennedy Capital Management LLC now owns 9,324 shares of the company’s stock worth $740,000 after buying an additional 296 shares in the last quarter. Institutional investors own 83.70% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.